CLINICAL_TRIALS
trial_result
· 2023-12-14
Clinical Trial Update: Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine [Phase 3]
Summary
Phase 3 trial update for BHV3000 (rimegepant) 75 mg in the acute treatment of migraine has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Acute Migraine | Phase 3 | Status: COMPLETED | Results posted: 2023-12-14